ArticleTranslational cancer research2025
Proteomics-based prognostic signature in colon adenocarcinoma patients with familial adenomatous polyposis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ethnic genomic differences in esophageal squamous cell carcinoma: Whole-exome sequencing of Han and Kazakh populations in China.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial adenomatous polyposis (FAP) is regarded as a precancerous stage of colon adenocarcinoma (COAD). COAD concurrent with FAP is quite rare in colorectal cancer screening. In order to create a new COAD prognostic prediction model and to shed light on the landscape of the tumor immune microenvironment in COAD, we examined differentially expressed genes (DEGs) between COAD and FAP in this study. Methods: DEGs between COAD and FAP were identified using proteomic technology. Expression matrix data for COAD were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Using multivariate and least absolute shrinkage and selection operator (LASSO) regression analyses, a prognostic risk model for COAD concurrent with FAP (COAD-FAP) was created. In the training and validation sets, the efficacy of the risk model was confirmed, respectively. A systematic analysis was conducted on the relationships between the prognostic signature and immunological score, tumor immune cell infiltration, and immune checkpoints. Results: A survival risk model was constructed using four prognostic genes: fatty acid-binding protein 4 ( Conclusions: These findings imply that the four COAD-FAP risk signatures could be a practical tool for forecasting prognostic risk, assessing immunotherapy efficacy, and personalizing customized treatment choices for COAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.